Abstract
Breast cancer is one of the most common malignancies affecting women; thus, much effort has been put into understanding the genetics of predisposition to breast cancer as well as identifying factors involved in tumor progression and cancer prognosis. Conventional genetics was used to map and clone the two breast / ovarian cancer predisposition genes, BRCA1 and BRCA2. However, the vast majority of breast cancer cases are of a sporadic nature, likely due to a combination of environmental and genetic factors. Other genes have been identified via the analysis of protein interactions, screens based on inverse genomics, yeast two-hybrid assays, far Westerns, GST-pull downs and chromatography / mass spectrometry have been used to identify a number of proteins that interact with BRCA1 or BRCA2. Biological characteristics such as expression levels, protein stability and phosphorylation as well as the biological roles of the BRCA proteins in DNA repair and transcription have also led to the identification of o ther proteins involved in breast cancer. Recent advances in microarray analysis have allowed the identification of further genetic factors by comparing the transcription profiles of cell lines with varying levels of BRCA1 expression or drug resistance and tumors from patientswith or without BRCA1 / 2 mutations or with different pathobiological types of tumors or prognoses. Additionally, microarray analysis at the DNA level allows for the identification of genes that have been amplified or deleted during cancer progression, and tumor tissue arrays can be used to analyze hundreds of samples simultaneously for the expression of previously identified genetic factors.
Current Genomics
Title: Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Volume: 3 Issue: 5
Author(s): M. K. Sauer
Affiliation:
Abstract: Breast cancer is one of the most common malignancies affecting women; thus, much effort has been put into understanding the genetics of predisposition to breast cancer as well as identifying factors involved in tumor progression and cancer prognosis. Conventional genetics was used to map and clone the two breast / ovarian cancer predisposition genes, BRCA1 and BRCA2. However, the vast majority of breast cancer cases are of a sporadic nature, likely due to a combination of environmental and genetic factors. Other genes have been identified via the analysis of protein interactions, screens based on inverse genomics, yeast two-hybrid assays, far Westerns, GST-pull downs and chromatography / mass spectrometry have been used to identify a number of proteins that interact with BRCA1 or BRCA2. Biological characteristics such as expression levels, protein stability and phosphorylation as well as the biological roles of the BRCA proteins in DNA repair and transcription have also led to the identification of o ther proteins involved in breast cancer. Recent advances in microarray analysis have allowed the identification of further genetic factors by comparing the transcription profiles of cell lines with varying levels of BRCA1 expression or drug resistance and tumors from patientswith or without BRCA1 / 2 mutations or with different pathobiological types of tumors or prognoses. Additionally, microarray analysis at the DNA level allows for the identification of genes that have been amplified or deleted during cancer progression, and tumor tissue arrays can be used to analyze hundreds of samples simultaneously for the expression of previously identified genetic factors.
Export Options
About this article
Cite this article as:
Sauer K. M., Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition, Current Genomics 2002; 3 (5) . https://dx.doi.org/10.2174/1389202023350264
DOI https://dx.doi.org/10.2174/1389202023350264 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets Current Concepts on the Management of Chordoma
Current Drug Therapy N7-Substituted-5-aryl-pyrrolo[2,3-d]pyrimidines Represent a Versatile Class of Potent Inhibitors of the Tyrosine Kinase c-Src
Mini-Reviews in Medicinal Chemistry Impact of PET on the Radiation Treatment of Hodgkins Lymphoma
Current Radiopharmaceuticals Design, Synthesis, <i>In Silico</i> and <i>In Vitro</i> Evaluation of Novel Pyrimidine Derivatives as EGFR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Schwann Cell Transplantation for CNS Repair
Current Medicinal Chemistry Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe
Current Drug Metabolism Synthesis and Properties of N1-(indan-5-yl)amidrazones Incorporating Piperazines and Related Congeners
Letters in Organic Chemistry Pharmacogenetics of Oxazaphosphorines and its Clinical Implications
Current Pharmacogenomics Overexpression of p62 Induces Autophagy and Promotes Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells through Promoting ERK Signaling Pathway
Current Cancer Drug Targets Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Quercetin and MicroRNA Interplay in Apoptosis Regulation in Ovarian Cancer
Current Pharmaceutical Design Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Pharmacogenetics of Obesity Drug Therapy
Current Molecular Medicine Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology PARP Inhibitors in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry